Bacterial Vaginosis Transmission and Treatment

Understanding BV Transmission Dynamics

The Centers for Disease Control and Prevention (CDC) previously stated that BV is not a classic sexually transmitted infection and that treating male partners does not prevent recurrence, based on six older randomized trials, however, this recommendation has been challenged by newer evidence 1, 2

Women who have never been sexually active rarely develop BV, and BV is associated with multiple sex partners and frequency of intercourse, according to the CDC 1, 2
The American College of Obstetricians and Gynecologists (ACOG) may recommend that male partners of women with recurrent BV receive treatment, including metronidazole 400 mg orally twice daily for 7 days and 2% clindamycin cream applied to penile skin twice daily for 7 days 3
The CDC and other health organizations recommend that both partners avoid all alcohol during metronidazole treatment and for 24 hours after completion to prevent disulfiram-like reactions, and refrain from unprotected intercourse for at least 14 days to allow treatment to take effect 3, 4

The treatment approach for male partners of women with recurrent BV includes metronidazole 400 mg orally twice daily for 7 days and 2% clindamycin cream applied to penile skin twice daily for 7 days, with a strength of evidence based on a 2025 landmark trial 3
No routine follow-up is needed for asymptomatic male partners, but women should return if symptoms persist or recur after treatment, and for pregnant women with BV, follow-up evaluation one month after treatment completion is recommended 3, 4